Malaria remains a significant contributor to the global burden of disease, with around 40% of
the world's population at risk of Plasmodium infections. The development of an effective …

Although there has been major recent progress in malaria vaccine development, substantial
challenges remain for achieving highly efficacious and durable vaccines against …

Summary Background The RTS, S/AS01 malaria vaccine targets the circumsporozoite
protein, inducing antibodies associated with the prevention of Plasmodium falciparum …

Background Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
induces an antibody response targeting multiple antigens that changes over time. This study …

Background The phase 3 trial of the RTS, S/AS01 malaria vaccine candidate showed
modest efficacy of the vaccine against Plasmodium falciparum malaria, but was not powered …

A major gap in the Plasmodium vivax elimination toolkit is the identification of individuals
carrying clinically silent and undetectable liver-stage parasites, called hypnozoites. This …

With increasing malaria control and goals of malaria elimination, many endemic areas are
transitioning from high-to-low-to-no malaria transmission. Reductions in transmission will …

Background Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
induces a complex antibody response that varies by orders of magnitude between …

Background Pro-and anti-inflammatory cytokines are important mediators of immunity and
are associated with malaria disease outcomes. However, their role in the establishment of …

Understanding the decay and maintenance of long-term SARS-CoV-2 neutralizing
antibodies in infected or vaccinated people and how vaccines protect against other SARS …